Amedisys Inc (NASDAQ:AMED) insider Denise M. Bohnert sold 362 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $220.00, for a total transaction of $79,640.00. Following the transaction, the insider now directly owns 9,095 shares in the company, valued at approximately $2,000,900. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

AMED opened at $234.16 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.02 and a quick ratio of 1.48. The firm has a fifty day moving average price of $202.10 and a 200 day moving average price of $187.33. Amedisys Inc has a 1 year low of $121.00 and a 1 year high of $237.28. The stock has a market cap of $7.58 billion, a P/E ratio of 60.66, a P/E/G ratio of 3.44 and a beta of 0.95.

Amedisys (NASDAQ:AMED) last posted its earnings results on Tuesday, July 28th. The health services provider reported $1.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.81 by $0.53. Amedisys had a net margin of 6.50% and a return on equity of 22.41%. The firm had revenue of $485.06 million during the quarter, compared to analysts’ expectations of $468.38 million. During the same period in the previous year, the business posted $1.21 EPS. The business’s revenue was down 1.6% compared to the same quarter last year. Equities analysts expect that Amedisys Inc will post 4.84 EPS for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Smithfield Trust Co. purchased a new stake in shares of Amedisys during the first quarter worth $27,000. Quadrant Capital Group LLC purchased a new stake in shares of Amedisys during the fourth quarter worth $40,000. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Amedisys during the first quarter worth $60,000. Anderson Fisher LLC purchased a new stake in shares of Amedisys during the first quarter worth $67,000. Finally, Fort L.P. purchased a new stake in shares of Amedisys during the first quarter worth $118,000. 88.31% of the stock is owned by institutional investors.

A number of research analysts have commented on AMED shares. UBS Group cut their target price on shares of Amedisys from $208.00 to $190.00 and set a “neutral” rating on the stock in a research report on Monday, May 11th. Oppenheimer reissued a “buy” rating and set a $215.00 target price on shares of Amedisys in a research report on Monday, April 27th. Raymond James lifted their price objective on shares of Amedisys from $210.00 to $255.00 and gave the company an “outperform” rating in a research note on Thursday. Jefferies Financial Group lifted their price objective on shares of Amedisys from $225.00 to $250.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, BidaskClub upgraded shares of Amedisys from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Five investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $215.67.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Further Reading: What is an investor looking for in an SEC filing?

Insider Buying and Selling by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.